Allograft rejection and immunosuppression are two major issues in transplantation medicine. The specific targeting of alloreactive T cells, the initiators and promoters of allograft rejection, would be a promising strategy to reduce unwanted T-cell responses and side effects of lifelong immunosuppression. The novel humanized monoclonal antibody GZ-αβTCR, specific for the human αβT-cell receptor, was tested in vitro and in vivo for its specificity and efficacy to modulate the αβT-cell compartment. GZ-αβTCR moderately induced apoptosis in resting αβT cells in vitro, an effect considerably amplified in activated T cells. A single dose of GZ-αβTCR significantly reduced human CD45 + CD3
INTRODUCTION
Efficacy and safety in solid-organ transplantation and SCT are based on the enduring development of new strategies for immunosuppression since 1954, when the first solid organ was successfully transplanted in humans. 1 Despite immunoprophylaxis, allograft rejection is still a major obstacle for transplantation success, necessitating lifelong immunosuppression [2] [3] [4] [5] with the well-known risk of infection, malignancy and chronic renal failure. Thus, immunosuppression has to carefully balance toxicity and rejection. [6] [7] [8] [9] Most of the current immunosuppressive regimens combine corticosteroids, calcineurin inhibitors (cyclosporine, tacrolimus), antimetabolites (mycophenolate mofetil, mycophenolic acid) and biologics [2] [3] [4] 9 that are-to reduce side effects-tailored to each patient's needs. Nevertheless, pharmacologics targeting initiators of alloreactivity more specifically are urgently needed.
Polyclonal antilymphocyte sera have been used in transplantation for almost 50 years with a significant impact on allograft survival. 10 Yet, polyclonal antithymocyte globulins target multiple cell populations including lymphocytes, natural killer (NK) cells, monocytes, macrophages and DCs. 9, 10 In addition, monoclonal biologics such as anti-CD52 antibody alemtuzumab do not target one specific cell type but a conglomerate of cells including T cells, B cells, NK cells, macrophages, DCs and eosinophils. 11 Application of those biologics is therefore associated with sustained immunosuppression and an inherent risk of infectious disease. [12] [13] [14] OKT3, recognizing CD3, the T-cell lineage marker, is more specific and highly effective, but is associated with severe side effects such as cytokine release syndrome, pulmonary oedema, aseptic meningitis and EBV-related post-transplant lymphoproliferative disease. [15] [16] [17] [18] Although preemptive corticosteroids mitigate some of these effects, production of OKT3 was discontinued.
The selective elimination of alloreactive αβT lymphocytes would be an essential step in rendering immunosuppression more specific, as it would still leave the patient with a certain degree of cell-based immune competence, namely γδ T cells, NK T cells and CD3
+ NK cells. To characterize the impact of the novel αβTCR-targeting mAb GZ-αβTCR on a healthy human T-cell compartment, we established an in vivo system-the NSG mouse equipped with human peripheral blood mononuclear cells (hu-PBL model)-described for its suitability to study immunemodulating drugs in vivo.
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Here, we show that GZ-αβTCR, a novel, humanized monoclonal antibody targeting the human αβTCR, has the capacity to potently induce apoptosis in activated αβT cells. Moreover, we show in vivo that GZ-αβTCR modulates the human αβT cell compartments with a preference for naive and CD4 + T cells, while sparing beneficial γδT cells. 0  24  48  72 240  0  24  48  72 240  0  24  48  72 240   0  24  48  72 240  0  24  48  72 240  0  24  48  72 240   0  24  48  72 240  0  24  48  72 240  0  24  48  72 240 10 ng/ml 
MATERIALS AND METHODS
αβT-cell antibody GZ-αβTCR was kindly provided by Genzyme, a Sanofi company (Cambridge, MA, USA).
Collection of human PBMCs
Human peripheral blood was obtained from healthy volunteers, in accordance with the Helsinki declaration. The human PBMCs (hPBMCs) were isolated by Ficoll density-gradient centrifugation (PAA Laboratories, Cölbe, Germany).
Cell cultures 1 × 10 6 cells/mL hPBMCs were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FCS (Biochrom, Berlin, Germany), L-glutamine (4 mM) and penicillin (50 U/mL)/ streptomycin (50 μg/mL) in 96-well U-bottom microtiter plates (Costar, Cambridge, MA, USA) and incubated at 37°C, 5% CO 2 and 95% humidity.
In vitro stimulation of hPBMCs
Freshly isolated hPBMCs were incubated with Dynabeads Human T-Activator CD3/CD28 in a 1:1 bead-to-cell ratio for 24 h according to the manufacturer's protocol (Invitrogen, Darmstadt, Germany).
CFDA SE proliferation assay
Freshly isolated PBMCs resuspended in PBS (1 × 10 7 cells/mL) were with 1.6 μM Vybrant reagent (CFDA SE Cell Tracer Kit, Invitrogen) for 9 min at room temperature in the dark. Labelling was terminated by adding FCS. Cells were then cultured as indicated. 
Antibodies and flow cytometry
Cells in single-cell suspensions were incubated with one or more of the following mAbs (15 min, room temperature, in the dark) specific for human cell-surface molecules: FITC-labelled CD3 (SK7), TCRγδ (11F2), CD27, phycoerythrin-labelled TCRγδ (11F2), CD62L, PerCP-labelled CD45 (2D1), CD3 (SK7), CD69 (L78) (all from BD Biosciences, Heidelberg, Germany), allophycocyanin (APC)-labelled CD3 (MEM-57) (Exbio, Prague, Czech Republic), CD45RA (HI100) (BioLegend, Fell, Germany), CD45RO (UCHL1) (eBioscience, Frankfurt, Germany), CD25 (M-A251), APC-H7-labelled CD8 (SK1) and CD28(CD28.2) (all from BD Biosciences) and VioBlue-labelled CD4 (VIT4) (Miltenyi Biotec GmbH). Surface-bound αβ mAb was detected by goat F(ab') 2 anti-human IgG(γ) R-phycoerythrin (Invitrogen). Dead cells were discriminated via Alexa Fluor 350 (Invitrogen). Detection of apoptosis was performed using the phycoerythrin-Annexin V Apoptosis Detection Kit I (BD Biosciences); intracellular stainings were performed with FIX&PERM (ADG, Kaumberg, Austria) (both according to the manufacturer's protocol) and the following antibodies: FITC-labelled IFN-γ(B27) (BioLegend) and APC-labelled tumour necrosis factor (TNF)-α (MAb11) (BD Biosciences).
Samples were acquired on a FACS Calibur or LSRII flow cytometer and analysed using CellQuest software (BD Biosciences, San Jose, CA, USA).
The engraftment rate of human cells was assessed as the ratio of human CD45 + cells to total mononuclear cells in the respective organ.
Cytokine detection
Serum aliquots of mice treated or not treated with GZ-αβTCR and of cell culture supernatant and respective controls were analysed for IFN-γ, TNF-α and IL-2 using the BIO-Plex Pro assay according to the manufacturer's protocol (BIO-RAD, München/Munich, Germany). Readout was performed with Flexmap 3D (Merck Millipore, Darmstadt, Germany). Concentration of cytokines was determined according to mean fluorescence intensity titration curves.
Statistics
Variances are shown as s.e.m. Significance was defined for a P-value of o0.05. Comparison of means was calculated with unpaired two-tailed t-test. Statistics were performed using GraphPad Prism software (GraphPad Software, San Diego, CA, USA).
RESULTS

Antibodies targeting αβTCR induce apoptosis in αβT cells in vitro
Humanized αβT-cell antibody BMA031, that is GZ-αβTCR, was tested for its ability to induce apoptosis in T cells of hPBMCs in the 
GZ-αβTCR potently induces apoptosis in activated αβT cells in vitro
To test the efficacy of GZ-αβTCR for induction of apoptosis in activated hPBMCs, the 24 h anti-CD3/CD28-stimulated hPBMCs (Figure 3b ). Whereas the proportion of αβT cells decreased because of apoptosis, γδT cells remained unaffected and their proportion compensatorily increased (Figures 4a and b) .
As GvHD is mainly caused by naive T cells that have not yet encountered their cognate antigen but get activated when primed on host DCs for recipient alloantigens, 22, 23 we analysed the immunologic memory compartments. No significant + cells (lower right) compared with initial value at day 0. Error bars represent s.e.m.; d0 and d3: ■ n = 18, □ n = 17; d6 SD: ■ n = 9, □ n = 8; d6 RA: ■ n = 9, □ n = 9. *P o 0.05; **P o0.01; ***P o0.001, ****P o0.0001.
drug-induced changes appeared in vitro; however, we observed a slight reduction of naive T cells (CD45RA   +   CD27 + CD62L + ) in anti-CD3/CD28-stimulated hPBMCs (Figure 4c ).
GZ-αβTCR reduces huCD45
+ cells in peripheral blood in hu-PBL model To study the effects of GZ-αβTCR in vivo, we used NOD-scidIL2ry null mice that were humanized similar to that in King et al., 19 who showed that huCD45 + cells engraft at high levels without the necessity of any host preconditioning. In this model, at 3 weeks post hPBMC injection, most of the engrafted huCD45 + cells in the spleen are CD3 + T cells plateauing until day 30. [19] [20] [21] 24, 25 This timeframe provides the opportunity to study the modulating effects of drugs and biologics such αβ mAb treatment in vivo without dealing with the underlying GvHD effects.
At 3 weeks after transplanting 2 × 10 7 hPBMCs i.v., huCD45 b) ) of GZ-αβTCR. Error bars present s.e.m.; d0 and d3: ■ n = 18, □ n = 17; d6 SD: ■ n = 9, □ n = 8; d6 RA: ■ n = 9, □ n = 9. *P o 0.05; **Po 0.01; ***P o0.001, ****P o0.0001.
GZ-αβTCR predominantly modulates CD4
+ αβT cells in the peripheral blood of hu-PBL model Analogous to King et al., 19 at 3 weeks post hPBMC injection, virtually all peripheral huCD45 + cells were CD3 + αβT cells (498%, data not shown), with a γδT cell proportion <1%. A single dose of GZ-αβTCR primarily downmodulated CD4 + αβ T cells to ∼ 60% of the initial value after single dose (Figure 5b ), a transient effect that was lost by day 6. In contrast, repetitive application (two doses) of GZ-αβTCR significantly reduced CD4 + αβT cells compared with PBS-treated controls at day 6 (P o 0.05, Figure 5b ). The simultaneous significant increase of CD8 + αβT cells (Figure 5b ) has to be considered as compensatory, as overall modulatory effect on CD4 + cells was below the overall downmodulation of huCD45 + cells (see also Figure 6b ).
Prolonged downmodulation of huCD45
+ cells in peripheral blood, spleen and BM in hu-PBL model by two doses of GZ-αβTCR A single dose of GZ-αβTCR did not affect the levels of engrafted huCD45 + CD3 + T cells in peripheral blood (see above), spleen and BM 6 days post administration (Figure 6a) . Furthermore, the CD4 + /CD8 + T-cell ratio (Figure 6a ) was unaffected in all organs. In contrast, repetitive GZ-αβTCR application reduced huCD45 + cells in peripheral blood (P o0.001) and in spleen (P o 0.0001), but not in BM, on day 6 after first treatment (Figure 6b ). Importantly, a significant decline of CD4 + T cells was observed after repetitive application of GZ-αβTCR in peripheral blood (14.05 ± 2.14 vs 37.96 ± 5.15, P o 0.001) and spleen (19.47 ± 2.27 vs 48.72 ± 3.80, P o0.0001; Figure 6b ). The modulating effect of GZ-αβTCR treatment on CD8 + cells in peripheral blood was less pronounced, but also significant (17.44 ± 1.2 vs 22.99 ± 2.36, P o 0.05). CD8 Figures 6a and b) .
GZ-αβTCR does not increase cytokine production GZ-αβTCR was well tolerated and not associated with a cytokine storm. Proinflammatory IFN-γ was detected only in small amounts, yet TNF-α and IL-2 were below detection limit in sera of hu-PBL-NSG mice at 4 h after GZ-αβTCR application (Figure 7a ). (Figure 7b) . Thus, this suggests that naive T cells recognizing recipient alloantigens will potently be deleted by GZ-αβTCR treatment.
GZ-αβTCR significantly reduces the number of naive T cells in vivo
Repetitive application of GZ-αβTCR modulates T cells in hu-HSC model In the hu-PBL model, a stably engrafted, non-xeno-alloreacting human T-cell compartment that is suitable to study drug-induced modulations without the bias of a putatively underlaying xenoGvHD ranges from day 21 to 30 post PBMC transplantation. Soon thereafter, mice develop GvHD-like symptoms. 19, 26 To exclude such potential bias in a hu-PBL model, we tested GZ-αβTCR in CD34 + -engrafted humanized NSG mice (hu-HSC-model) 20 that display all haematopoietic lineages of a healthy human immune system. Repetitive application of GZ-αβTCR significantly reduced huCD45 + CD3 + T cells as shown for peripheral blood, spleen and BM (each P o 0.05) at day 6 in comparison with control mice. Again, GZ-αβTCR preferentially modulated CD4 + cells, although both CD4 + and CD8 + T cells were significantly reduced in spleen (P o 0.05) but not in BM (Figure 8) . Moreover, GZ-αβTCR treatment significantly increased the proportion of γδT cells within CD3
+ cells in this model as well (P o 0.05, Figure 8 ).
DISCUSSION
Immunosuppressive targeting of αβTCR therapy is not new, but has been conducted in clinical settings as well as various model systems. Mouse anti-rat αβTCR mAb (R73) was successful in experimental autoimmune arthritis and neuritis, 27, 28 and was highly effective in supporting long-term survival of cardiac allografts in rats. 29 Anti-αβ-T-cell receptor antibodies improved regeneration of nerve allografts and prevented allograft rejection in animal models for small-bowel, skin, kidney and corneal transplants. [30] [31] [32] [33] [34] BMA031, a mouse anti-human αβTCR mAb, was shown to induce apoptosis in T cells, whereas the susceptibility to apoptosis was higher in activated cells. 35 Furthermore, BMA031 showed efficiency in clinical phase II and III studies in humans, 35 where it significantly reduced renal allograft rejection and increased allograft survival. Administration of BMA031 was not associated with severe adverse reactions and toxic side effects were modest, [35] [36] [37] but a major limitation of BMA031 was the rapid development of human anti-mouse antibodies, impairing efficacy and application for longer periods of time. 37 Thus, humanization of the antibody seemed a highly promising strategy to optimize the therapeutic utility of BMA031. We tested humanized BMA031: GZ-αβTCR for its efficacy to specifically target (activated) αβ T cells in vitro and in vivo in two model systems (hu-PBL-and hu-HSC-NSG), both suitable to study human T cells in context with human allograft rejection. 19, 20, [38] [39] [40] GZ-αβTCR significantly modulated hu CD45 + CD3 + cells in peripheral blood, spleen and BM. Single application downmodulated T-cell numbers only transiently, with a T-cell decline similar to what was reported for type I diabetes patients following anti-CD3 mAb therapy (Teplizumab), which was described as transient margination. 41 In contrast, repetitive application of GZ-αβTCR significantly decreased huCD45 + T cells in peripheral blood and spleen 3 days after second administration (day 6). Congruent with phase I and II studies using BMA031, [35] [36] [37] GZ-αβTCR did not increase the production of proinflammatory cytokines IFN-γ, TNF-α and IL-2 either in vivo or in vitro, suggesting that a cytokine release syndrome, as reported after OKT3, is less likely to occur. 15, 36 Two findings of the study demonstrate significant clinical relevance. First, GZ-αβTCR induced apoptosis marginally in native but potently in anti-CD3/CD28-prestimulated αβT cells in vitro. This capacity of GZ-αβTCR to discriminate activated versus nonactivated T cells allows us to assume a preferential elimination of naive αβ T cells during the induction phase of GvHD, where naive T cells get primed and activated on host DCs for recognition of recipient immunogens. 42, 43 The observed preferential depletion of those T cells that are detrimental in transplant settings directly relates to emerging clinical trials performing CD45RA depletion from the haematopoietic graft to prevent a GvHD. 22, 23 This will allow us to significantly reduce the risk of allograft rejection but spare memory T cells, desirable pathogen-reactive immunity, in the patient.
Second, GZ-αβTCR significantly reduced CD4 + cells in peripheral blood and spleen compared with control, and considerably decreased naive T cells in healthy human T cells in vivo. As naive CD4 + T cells create the basis for tissue-destructive cytolytic T-cell responses, the selective elimination of both CD4 + and naive T cells is a major step forward in the attempt to reduce graft rejection and prevent GvHD after transplantation.
Moreover, as a mAb that is strictly targeting αβT cells, GZ-αβTCR spares CD3
+ non-αβTCR + T cells that are non-alloreactive, but pathogen-reactive such as γδT cells, invariant NK T cells and also NK cells, rendering αβTCR-targeting mAbs superior to other biologics like antithymocyte globulin, alemtuzumab and OKT3. [44] [45] [46] GZ-αβTCR-as we show-spared non-αβ immune effector cells, namely γδT cells, that are endowed with unique functional and antigen specificities, execute a broad spectrum of cell-cell interactions and have potent immune regulatory capacity. 47 Their continuance is of specific significance early after haematopoietic SCT when patients, still immunocompromised, suffer from a high risk of lymphoproliferative disorders 48 and relapse of the underlaying disease, as γδT cells can suppress B-cell expansion, 49 regulate T-cell leukaemia and exert potent antitumoural activity. [50] [51] [52] [53] [54] [55] [56] Furthermore, the key role of γδT cells in primary immune responses is undisputed in CMV, HSV-1 and Candida albicans infections, pathogens that are frequent after transplantation. [57] [58] [59] In addition, γδT cells are crucial modulators of immune responses and decisive in the induction and maintenance of tolerance in various physiological settings [60] [61] [62] [63] and can directly promote allograft survival. 64 GZ-αβTCR was well tolerated, congruent with the bland cytokine signature obtained in vitro when crosslinking αβT cell TCR with GZ-αβTCR. Both findings stand in clear contrast to the life-threatening cytokine release storms observed after OKT3 treatment. 15, 36 Also, the transient GZ-αβTCR-mediated effects on the T-cell compartment suggest that its application is nontoxic but safe and repeatable, when immunosuppressive intervention is needed.
The reason for GZ-αβTCR-mediated selectivity for CD4 + cells is not clear, although similar results have been observed by others with anti-CD3, anti-CD3(Fab) fragments and anti-TCRβ mAbs. [65] [66] [67] [68] In light of the intriguing recent finding that during selection in thymopoiesis asymmetric death is the key determinant of the CD4/CD8 ratio, it seems reasonable to assume intrinsically disparate cascades of transcriptional regulators and programming segregating the CD4 versus the CD8 lineage in their susceptibilies to activation, anergy and death. 69 In summary, here we demonstrate the efficient and selective depletion of activated αβT cells both in vitro and in vivo with the novel, humanized mAb GZ-αβTCR-targeting human αβTCR. We demonstrate for the first time in vitro and in vivo in two model systems that GZ-αβTCR preferentially deletes CD4 + cells and significantly reduces the naive T-cell compartment, the trigger and driver of GvHD.
Moreover, by sparing γδT cells, GZ-αβTCR preserves a considerable dimension of cellular immune competence and regulation within the recipient. GZ-αβTCR was well tolerated, and was not associated with an increase in cytokine production. When viewed in combination, these findings strongly suggest GZ-αβTCR as an utmost potent agent for the prevention of allograft rejection and GvHD in clinical settings.
